Financial Performance Overview
Anuh Pharma Limited reported mixed financial results for FY 2025-26, with total revenue increasing by 16.65% to ₹77,166 lakhs (₹772 crore) from ₹66,151 lakhs in the previous year. However, net profit declined by 13.3% to ₹4,104.61 lakhs (₹41.05 crore) from ₹4,735.19 lakhs, resulting in basic EPS of ₹4.10 compared to ₹4.72 in FY25. The net profit margin compressed to 5.34% from 7.20%.
Operational Highlights & Capacity Expansion
The company expanded its manufacturing capacity from 2200 MTPA to 2400 MTPA at its Boisar facility, inaugurating the INT-1A plant on 15th July 2025 which added 200 MT/annum capacity. Anuh Pharma successfully passed USFDA inspection with no Form 483 observations and received EDQM compliance certification. The company holds multiple regulatory approvals including 8 CEP certifications (Pyrazinamide, Erythromycin, Azithromycin, Sulfadoxine, Sulfadimethoxine, etc.) and WHO prequalifications for several APIs.
Product Development & Business Growth
During FY26, the company launched six new products including Vildagliptin, Allopurinol, Dapagliflozin Propanediol Monohydrate, and Sulfadimethoxine. The export business expanded with 40 new customers, reaching over 85 countries. Major contributions came from Anti-malarial, Antibiotic, Expectorant, and Antidiabetic segments. R&D expenditure increased to ₹532.00 lakhs from ₹447.02 lakhs, focusing on process improvement and new API development.
Corporate Actions & Capital Structure
The Board recommended a final dividend of ₹1.50 per equity share (30% of face value ₹5) and had previously approved a 1:1 bonus share issue in July 2025, increasing share capital to ₹5,011.20 lakhs from ₹2,505.60 lakhs. The company maintained a strong balance sheet with total equity of ₹35,222.24 lakhs and negative net debt of ₹5,291.94 lakhs. Return on Capital Employed stood at 15.92% while Return on Equity was 12.10%.
Governance & Compliance Matters
The AGM is scheduled for 12th August 2026 to approve financial statements, dividend declaration, reappointment of directors, and special business including remuneration revisions for joint managing directors. The company maintains robust corporate governance with a 12-member board and various committees. CSR expenditure of ₹1,11,17,455 was directed toward healthcare, education, and environmental sustainability initiatives.
Future Outlook & Strategic Initiatives
Anuh Pharma targets 15-16% revenue CAGR supported by new product launches (5-6 APIs planned for FY27) and market expansion into US, Europe, CIS, and LATAM regions. The company is focusing on therapeutic areas including Diabetes, Hypertension, CNS, and Dermatology, while exploring inorganic growth opportunities through mergers and acquisitions for rapid market access.